🚀 VC round data is live in beta, check it out!
Largest Biopharmaceuticals Public Companies in China
Benchmark revenue and EBITDA valuation multiples for public comps like
Jiangsu Hengrui Pharma, Hansoh Pharma, Innovent Biologics, Sichuan Biokin and Akeso.
 | $8 | +13% | $55B | $49B | 10.3x | 35.8x | ||
| $5 | +60% | $30B | $25B | 11.2x | 27.9x | ||
| $11 | +63% | $19B | $17B | 8.6x | 65.9x | ||
| $45 | +9% | $19B | $18B | 54.3x | (483.4x) | ||
| $17 | +57% | $16B | $16B | 29.5x | (325.9x) | ||
| $8 | -3% | $14B | $13B | 2.1x | 14.6x | ||
| $22 | -26% | $13B | $13B | 9.1x | 27.0x | ||
| $1 | +49% | $13B | $12B | 3.0x | 11.5x | ||
| $9 | +55% | $10B | $10B | 14.7x | — | ||
| $18 | +189% | $10B | $10B | 16.3x | 47.3x | ||
| $8 | +67% | $10B | $9B | 9.3x | 29.9x | ||
| $4 | +17% | $10B | $13B | 2.1x | 11.4x | ||
| $5 | -7% | $9B | $9B | 1.3x | 10.4x | ||
| $8 | +26% | $9B | $9B | — | — | ||
| $5 | -5% | $8B | $7B | 2.7x | 14.4x | ||
| $6 | -40% | $7B | $7B | — | — | ||
| $3 | +91% | $7B | $6B | 2.7x | 4.8x | ||
| $4 | -12% | $7B | $7B | 1.4x | 7.6x | ||
| $14 | +12% | $6B | $6B | — | — | ||
| $6 | +99% | $6B | $6B | — | — | ||
| $9 | +35% | $6B | $5B | 7.8x | 23.4x | ||
| $1 | -14% | $6B | $6B | — | — | ||
| $10 | +106% | $6B | $6B | 5.9x | 28.4x | ||
| $4 | -24% | $6B | $4B | 1.7x | 12.0x | ||
| $2 | -16% | $5B | $7B | 4.6x | (86.0x) | ||
| $8 | +2% | $5B | $4B | 3.9x | 12.1x | ||
| $5 | +29% | $5B | $5B | 13.4x | (74.1x) | ||
| $12 | -2% | $5B | $5B | — | — | ||
| $1 | +29% | $5B | $10B | 0.2x | 3.8x | ||
| $2 | +73% | $4B | $4B | 3.0x | 12.1x | ||
| $3 | -10% | $4B | $5B | — | — | ||
| $2 | -22% | $4B | $4B | 4.4x | 11.9x | ||
| $5 | +2% | $4B | $3B | 1.7x | 6.4x | ||
| $5 | +40% | $4B | $4B | — | — | ||
| $2 | +48% | $4B | $3B | 9.2x | 49.0x | ||
| $2 | +21% | $4B | $4B | 2.7x | 15.1x | ||
| $2 | -9% | $4B | $4B | 5.2x | 16.1x | ||
| $9 | -13% | $4B | $4B | 6.5x | — | ||
| $14 | -9% | $4B | $4B | 21.0x | 468.3x | ||
| $4 | +1% | $4B | $3B | 3.9x | 11.1x | ||
| $9 | -- | $4B | $4B | — | — | ||
| $0 | -9% | $4B | $3B | — | — | ||
| $4 | -2% | $3B | $2B | 2.2x | 6.1x | ||
| $2 | +11% | $3B | $4B | 3.5x | 16.9x | ||
| $2 | -9% | $3B | $3B | 5.0x | 15.0x | ||
| $39 | +46% | $3B | $3B | 11.2x | (44.1x) | ||
| $3 | +2% | $3B | $3B | — | — | ||
| $6 | -- | $3B | $4B | — | — | ||
| $7 | +6% | $3B | $3B | — | — | ||
| $3 | +12% | $3B | $3B | — | — | ||
| $2 | -6% | $3B | $3B | 2.4x | 10.4x | ||
| $1 | +15% | $3B | $3B | 2.1x | 11.2x | ||
| $3 | +31% | $3B | $3B | 1.8x | 10.7x | ||
| $2 | +6% | $3B | $1B | 0.6x | 3.8x | ||
| $2 | +27% | $3B | $3B | 7.7x | 24.4x | ||
| $3 | -3% | $3B | $3B | 1.6x | 6.8x | ||
| $6 | -12% | $3B | $3B | 5.5x | — | ||
| $6 | +13% | $3B | $3B | — | — | ||
| $2 | +6% | $3B | $3B | — | — | ||
| $3 | -5% | $2B | $1B | 2.1x | (86.4x) | ||
| $2 | +124% | $2B | $2B | — | — | ||
| $1 | +21% | $2B | $2B | — | — | ||
| $6 | -- | $2B | $2B | — | — | ||
| $6 | +1% | $2B | $2B | 23.8x | (14.3x) | ||
| $1 | -3% | $2B | $2B | 3.8x | 13.9x | ||
| $2 | +15% | $2B | $3B | 2.7x | 14.1x | ||
| $2 | +3% | $2B | $2B | 5.6x | 16.3x | ||
| $6 | +82% | $2B | $2B | 21.2x | — | ||
| $1 | +4% | $2B | $2B | 2.8x | 18.6x | ||
| $3 | -18% | $2B | $2B | 5.8x | 15.2x | ||
| $4 | +34% | $2B | $2B | 10.9x | — | ||
| $3 | -2% | $2B | $2B | — | — | ||
| $10 | +111% | $2B | $2B | 7.7x | — | ||
| $3 | -4% | $2B | $2B | 161.6x | (35.0x) | ||
| $1 | +237% | $2B | $2B | 35.6x | (31.3x) | ||
| $2 | -24% | $2B | $2B | — | — | ||
| $3 | +26% | $2B | $1B | 7.9x | 31.2x | ||
| $5 | -22% | $2B | $1B | 4.7x | (55.5x) | ||
| $1 | -6% | $2B | $2B | — | — | ||
| $2 | -7% | $2B | $2B | 4.0x | 35.7x | ||
| $2 | +1% | $2B | $2B | 3.5x | 11.8x | ||
| $4 | +1% | $2B | $1B | — | — | ||
| $4 | -1% | $1B | $755M | — | — | ||
| $4 | -- | $1B | $2B | — | — | ||
| $2 | +59% | $1B | $1B | 6.9x | 12.4x | ||
| $3 | +118% | $1B | $2B | 7.9x | 36.5x | ||
| $4 | -20% | $1B | $2B | — | — | ||
| $3 | +2% | $1B | $1B | — | — | ||
| $1 | +17% | $1B | $1B | 9.9x | — | ||
| $3 | -- | $1B | $1B | 35.6x | (26.2x) | ||
| $3 | -9% | $1B | $1B | — | — | ||
| $3 | +14% | $1B | $1B | — | — | ||
| $1 | +30% | $1B | $1B | — | — | ||
| $2 | +5% | $1B | $1B | — | — | ||
| $0 | -10% | $1B | $797M | 0.4x | 4.5x | ||
| $7 | +37% | $1B | $876M | 6.8x | 22.1x | ||
| $3 | -13% | $1B | $1B | — | — | ||
| $8 | +13% | $1B | $959M | 5.3x | 16.0x | ||
| $2 | -8% | $1B | $766M | 5.3x | 9.5x | ||
| $0 | -14% | $937M | $1B | — | — |
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.